NCT04038619 2026-03-18
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
372 trialsNCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT00515372 2026-03-09
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05159050 2026-02-25
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
University of Iowa
Phase 1 Terminated
NCT05603910 2026-02-24
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
University of Miami
Phase 1 Recruiting
NCT04893434 2026-02-20
Novel Imaging Technique to Assess Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03252938 2026-02-19
INSIGHT
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1 Active not recruiting
NCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT06623396 2026-02-11
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05082259 2026-02-10
ASTEROID
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT02195973 2026-02-09
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Completed
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03120624 2026-02-04
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
Phase 1 Active not recruiting
NCT07292818 2026-02-04
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT07030283 2026-02-02
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
Phase 1 Recruiting
NCT02405221 2026-01-29
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT05542407 2026-01-29
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05636111 2026-01-22
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06856499 2026-01-09
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
Phase 1 Recruiting
NCT06964009 2026-01-08
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT04670068 2025-12-22
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03245892 2025-12-17
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06795009 2025-12-11
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06107868 2025-12-08
GyneRep
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05316129 2025-12-05
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT02869217 2025-12-03
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
Phase 1 Active not recruiting
NCT07106827 2025-11-24
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
Phase 1 Recruiting
NCT06342986 2025-11-12
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT04615013 2025-10-30
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04220827 2025-10-27
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03325634 2025-10-23
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer
University of Colorado, Denver
Phase 1 Completed
NCT04169763 2025-10-22
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03604315 2025-10-14
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03634267 2025-10-14
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05039801 2025-10-14
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05866679 2025-10-14
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
M.D. Anderson Cancer Center
Phase 1 Suspended
NCT06191133 2025-10-02
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT06533332 2025-09-18
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Phase 1 Recruiting
NCT06305299 2025-09-15
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT02637934 2025-09-10
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting